$4.34
+0.04
(+0.93%)▲
Live
4.26%
Downside
Day's Volatility :13.26%
Upside
9.39%
4.86%
Downside
52 Weeks Volatility :84.78%
Upside
84.0%
Period | Biora Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -38.37% | 0.0% |
6 Months | -29.05% | 0.0% |
1 Year | -82.38% | 0.0% |
3 Years | -97.74% | -23.0% |
Market Capitalization | 20.2M |
Book Value | -$24.85 |
Earnings Per Share (EPS) | -49.3 |
Wall Street Target Price | 9.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -4964.15% |
Return On Assets TTM | -125.06% |
Return On Equity TTM | 0.0% |
Revenue TTM | 860.0K |
Revenue Per Share TTM | 0.33 |
Quarterly Revenue Growth YOY | 15800.0% |
Gross Profit TTM | 1.2M |
EBITDA | -67.5M |
Diluted Eps TTM | -49.3 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.88 |
EPS Estimate Next Year | -1.16 |
EPS Estimate Current Quarter | -0.45 |
EPS Estimate Next Quarter | -0.42 |
What analysts predicted
Upside of 124.65%
Sell
Neutral
Buy
Biora Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Biora Therapeutics Inc | -24.27% | -29.05% | -82.38% | -97.74% | -97.74% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Biora Therapeutics Inc | NA | NA | NA | -0.88 | 0.0 | -1.25 | NA | -24.85 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Biora Therapeutics Inc | Buy | $20.2M | -97.74% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Biora Therapeutics Inc
Revenue is down for the last 2 quarters, 542.0K → 318.0K (in $), with an average decrease of 41.3% per quarter
Netprofit is up for the last 4 quarters, -73.45M → 6.46M (in $), with an average increase of 269.8% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 166.5%
Athyrium Capital Management LP
Vanguard Group Inc
Geode Capital Management, LLC
Northern Trust Corp
TWO SIGMA SECURITIES, LLC
BlackRock Inc
progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.
Organization | Biora Therapeutics Inc |
Employees | 58 |
CEO | Mr. Aditya P. Mohanty M.B.A. |
Industry | Miscellaneous |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$4.34
+0.93%
Invesco Bulletshares 2025 Hi
$4.34
+0.93%
Schwab International Dividend Equity Etf
$4.34
+0.93%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$4.34
+0.93%
Lightpath Technologies Inc
$4.34
+0.93%
Vaneck Vectors Global Alternative Energy Etf
$4.34
+0.93%
First Trust Flexible Municipal High Income Etf
$4.34
+0.93%
Drx Dly Reg Bank Bull 3x
$4.34
+0.93%
Graniteshares 2x Long Pltr Daily Etf
$4.34
+0.93%